DETECTION OF MILNACIPRAN BIOTRANSFORMATION PRODUCTS IN URINE UNDER TLC-SCREENING

Authors

  • S. V. Baiurka NATIONAL UNIVERSITY OF PHARMACY, KHARKIV
  • S. A. Karpushyna NATIONAL UNIVERSITY OF PHARMACY, KHARKIV
  • E. Yu. Akhmedov NATIONAL UNIVERSITY OF PHARMACY, KHARKIV

DOI:

https://doi.org/10.11603/mcch.2410-681X.2021.i4.12730

Keywords:

milnacipran, chemical-toxicological analysis, biofluids, metabolites, thin layer chromatography, color reactions

Abstract

Introduction. Thin layer chromatography screening is the most accessible type of screening procedure that is used in forensic toxicology. For the analytical diagnosis of drug poisoning by the TLC method, it is important to develop conditions for the detection of both native compounds and products of their biotransformation in the biological samples.

The aim of the study – to develop a method for isolating the antidepressant drug milnacipran from human urine in the presence of its biotransformation products and determine the conditions for their detection by thin layer chromatography, suitable for analytical diagnostics of thymoleptic intoxication.

Research Methods. The study was carried out with human urine samples collected after taking a single therapeutic dose of milnacipran. The urine was subjected to the acid hydrolysis and the antidepressant and its metabolites were extracted from the destructate with chloroform from an alkaline medium at pH 8–9. Concomitant endogenous admixtures were removed by extraction with diethyl ether from an acidic medium at pH 1. For the chromatographic study of the extracts, four mobile phases recommended by the International Association of Forensic Toxicologists for TLC screening of drugs, and Merk chromatographic plates were used. Colour reactions were carried out on pieces of chromatographic plates with a range of chromogenic reagents most common used in chemical-toxicological analysis. Metabolites were identified by electron impact mass spectrometry.

Results and Discussion. The parameters of the chromatographic mobility of the main (N-desethylmylnacipran) and minor (the structure could not be established) metabolites of milnacipran were determined, as well as the results of the reactions of their visualization with chromogenic reagents.

Conclusions. Isolation conditions for milnacipran and its biotransformation products from human urine have been proposed. The method of the detection of the native compound and milnacipran metabolites in the extracts from urine by TLC and colour reactions after taking a single therapeutic dose of the drug has been developed. The methods are recommended for use in the practice of forensic and clinical toxicology.

References

Raouf, M., Glogowski, A.J., Bettinger, J.J., & Fudin, J. (2017). Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia. J. Clin. Pharm. Ther., 42, 513-517.

Mashkovskii, M.D. (2020). Medicines. Moscow: Izdatelstvo Novaya Volna [in Russian].

Levine, M., Carry, A.T., & Connor, A. (2011). Cardiotoxicity and serotonin syndrome complicating a Milnacipran overdose. J. Med. Toxicol., 7 (4), 312-316.

Fanton, L., Bevalot, F., & Grait, H. (2008). Fatal intoxication with milnacipran. J. Forensic Leg. Med., 15 (6), 388-390.

Moffat, A.C., Osselton, M.D., & Widdop, B. (2011). Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. (4-th ed.). London, Chicago: Pharmaceutical Press.

Li, F., Chin, C., Wangsa, J., & Ho, J. (2012). Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. Drug. Metab. Dispos., 40 (9), 1723-1735.

Kanalaa, K., Hwisac, N.T., & Chanduc, B.R. (2013). Bioanalytical method development and validation of milnacipran in rat plasma by LC–MS/MS detection and its application to a pharmacokinetic study. J. Pharm. Anal., 3 (6), 481-488.

Baiurka, S.V., Karpushyna, S.A., & Moroz, V.P. (2016). Analytical diagnosis of milnacipran poisoning. Clin. Pharmacy, 20 (4), 62-65.

Published

2022-02-23

How to Cite

Baiurka, S. V., Karpushyna, S. A., & Akhmedov, E. Y. (2022). DETECTION OF MILNACIPRAN BIOTRANSFORMATION PRODUCTS IN URINE UNDER TLC-SCREENING. Medical and Clinical Chemistry, (4), 30–34. https://doi.org/10.11603/mcch.2410-681X.2021.i4.12730

Issue

Section

ORIGINAL INVESTIGATIONS